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Rare Copy Number Variants Disrupt Genes Regulating
Vascular Smooth Muscle Cell Adhesion and Contractility
in Sporadic Thoracic Aortic Aneurysms and Dissections
Siddharth K. Prakash,1 Scott A. LeMaire,2,3 Dong-Chuan Guo,4 Ludivine Russell,2 Ellen S. Regalado,4
Hossein Golabbakhsh,4 Ralph J. Johnson,4 Hazim J. Safi,5 Anthony L. Estrera,5 Joseph S. Coselli,2,3
Molly S. Bray,1 Suzanne M. Leal,1 Dianna M. Milewicz,4 and John W. Belmont1,*
Thoracic aortic aneurysms and dissections (TAAD) cause significant morbidity and mortality, but the genetic origins of TAAD remain
largely unknown. In a genome-wide analysis of 418 sporadic TAAD cases, we identified 47 copy number variant (CNV) regions that
were enriched in or unique to TAAD patients compared to population controls. Gene ontology, expression profiling, and network anal-
ysis showed that genes within TAAD CNVs regulate smooth muscle cell adhesion or contractility and interact with the smooth muscle-
specific isoforms of a-actin and b-myosin, which are known to cause familial TAADwhen altered. Enrichment of these gene functions in
rare CNVs was replicated in independent cohorts with sporadic TAAD (STAAD, n ¼ 387) and inherited TAAD (FTAAD, n¼ 88). The over-
all prevalence of rare CNVs (23%) was significantly increased in FTAAD compared with STAAD patients (Fisher’s exact test, p ¼ 0.03).
Our findings suggest that rare CNVs disrupting smoothmuscle adhesion or contraction contribute to both sporadic and familial disease.Introduction
Thoracic aortic aneurysms and dissections (TAAD) cause
more than 8000 deaths in the United States every year.1
Progressive enlargement of the aorta is usually asymptom-
atic until a catastrophic event occurs, typically an acute
aortic dissection leading to pericardial tamponade, stroke,
acute aortic regurgitation, or other complications.2 The
pathological hallmark of TAAD is ‘‘medial degeneration,’’
previously termed cystic medical necrosis.3 The medial
layer of the aorta is normally composed of laminar smooth
muscle cells (SMCs) surrounded by a tightly packed mesh-
work of elastin and collagen that provides tensile strength
and flexibility. Medial degeneration corresponds to pro-
gressive depletion of elastin fibers from the media and
predisposes to dissection or rupture.4 The annual risk of
sudden death from an enlarged thoracic aneurysm as
a result of an acute aortic dissection is more than 10%.5
Timely surgical repair of aneurysms can prevent death.
However, there are few recognized risk factors for the
development of thoracic aneurysms and no reliable
biomarkers that might be used for screening. The aortic
segment affected, age of onset, and rate of enlargement
of aneurysms are heterogeneous.6 Eighty percent of
TAAD patients do not disclose a family history of vascular
disease (sporadic thoracic aortic aneurysms, or STAAD).7
Because of these challenges, the genetic causes of STAAD
have remained largely unknown. Prospective identifica-
tion of patients at risk for TAAD via a genetic strategy
will be critical to prevent sudden deaths from this treatable
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The AmericanTwenty percent of TAAD patients have an affected rela-
tive (familial thoracic aortic aneurysm and dissection, or
FTAAD), and the phenotype is primarily inherited in an
autosomal-dominant manner characterized by variable
expression and incomplete penetrance.8 Large pedigrees
with multiple affected members have been assembled to
allow the genetic mapping of seven distinct loci for FTAAD
on 5q13-q14, 16p13.12-p13.13, 11q23.3-q24, 3p24-p25,
9q22, 10q22-q24, and 15q24-q26 (MIM 607087, 132900,
607086, 6103080, 608967, 611788, and unassigned).
Four of these genes have been identified: ACTA2 (MIM
102620, 10q23), MYH11 (MIM 160745, 16p13), TGFBR1
(MIM 190181, 9q22), and TGFBR2 (MIM 190182,
3p22).9–12 ACTA2 and MYH11 encode the smooth
muscle-specific isoforms of actin and myosin, which are
primary components of the contractile apparatus. The
TGF-b pathway regulates the expression of contractile
proteins by vascular SMCs.13 Together, these genes
account for less than 20% of the familial cases, suggesting
that additional locus heterogeneity could be extensive.
Similarly, genetic syndromes that predispose to the devel-
opment of thoracic aneurysms are also caused by muta-
tions of SMC adhesive or cytoskeletal proteins such as
fibrillin-1 (FBN1 [MIM 134797]) in Marfan syndrome
(MIM 154700) and filamin-A (FLNA [MIM 300017]) in
patients with X-linked periventricular nodular heterotopia
(MIM 300049) and thoracic aortic disease.14 Both proteins
perform an essential function in vascular development
by anchoring actin fibers to focal adhesions on SMC
membranes.15 Based on these observations, we hypothe-
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mutation of contractile proteins or impairment of SMC
adhesion predisposes to TAAD.16
Unanswered questions concerning the pathogenesis of
TAAD include how mutations in SMC contractile proteins
lead to aortic pathology and why the phenotypic manifes-
tations of identical mutations are so variable. We propose
that variations in currently unidentified modifying genes
may exert a profound influence on an individual’s suscep-
tibility to aneurysm disease. These genetic variants almost
certainly interact with environmental factors such as age,
gender, hypertension, and tobacco use to determine an
individual’s total risk for TAAD.17 According to this model,
gene products that relay environmental signals to regulate
smooth muscle functions are ideal candidates to modify
the pathogenesis of TAAD.
Copy number variations (CNVs) have been shown to
confer increased risk for common multifactorial diseases
such as autism (MIM 209850) and schizophrenia (MIM
181500), as well as congenital cardiovascular disorders
such as tetralogy of Fallot (TOF [MIM 187500]).18–20 These
findings are consistent with a genetic model wherein any
of a large number of individually rare copy number muta-
tions contribute to disease causation or predisposition.21
We therefore hypothesized that individually rare structural
variants could contribute to disease risk in TAAD and
that such variants are likely enriched within genes
involved in vascular SMC contractility.Subjects and Methods
TAAD and Control Cohorts
The studyprotocolwas approvedby the institutional review
boards at Baylor College of Medicine and University of
Texas Health Science Center at Houston (UTHSCH). After
obtaining written informed consent, we enrolled non-
Hispanic patients of European descent with sporadic
ascending aortic aneurysms or thoracic aortic dissections
(STAAD) who were evaluated at the Texas Heart Institute
at St. Luke’s Episcopal Hospital and Methodist Hospital
(BCM cohort) or Memorial Hermann Hospital (UTHSCH
cohort). BCM cases included 418 unrelated individuals,
269 males and 149 females, with a mean age of 63 years
(32–86 years). The replication cohort consisted of 387 unre-
lated individuals enrolled at UTHSCH. In all patients, the
diagnosis was confirmed by echocardiography, computed
tomography, magnetic resonance imaging, or aortography.
We excluded patients who were less than 31 years of age
because of the higher prevalence of Mendelian disorders in
this age group.We also excluded patientswith aortic lesions
associatedwith trauma, infection, aortitis, syndromic forms
of TAAD, or connective tissue disorders, patientswith a first-
degree relative with thoracic aortic aneurysm or dissection,
patients with an isolated intramural hematoma, pene-
trating aortic ulcer, or pseudoaneurysm, and patients who
received packed red blood cell, whole blood, or platelet
transfusions within 72 hr of blood collection.744 The American Journal of Human Genetics 87, 743–756, DecembThe familial TAAD cohort (FTAAD) consisted of 88
affected probands from unrelated families with multiple
members with TAAD who did not have a genetic mutation
or syndrome identified as the cause of the inherited TAAD.
The proband and family members were considered to be
affected if they had dissection of the thoracic aorta,
surgical repair of an ascending aneurysm, or dilatation of
the ascending aorta greater than 4.5 cm based on echocar-
diography images of the aortic diameter at the sinuses of
Valsalva and/or the ascending aorta.
The primary controls for the study were Illumina geno-
types of 6809 subjects obtained from the Database of
Genotypes and Phenotypes (dbGAP). The characteristics
of the five control cohorts and genotypes are listed in
Table S1 available online. Our analysis was confined to
unrelated individuals of European descent over 31 years
of age from each data set. Phenotypic data relevant to
TAAD were not available from any of the multiple control
samples used.
DNA Extraction and Genotyping
DNA was extracted from saliva, whole blood, or buffy coat
samples collected from each patient at enrollment and
stored at 80C until DNA extraction. The quantity of
double-stranded DNA was measured with PicoGreen (Invi-
trogen). Samples with a DNA concentration below 40 mg/
ml were concentrated with a Speed Vac system; samples
with a DNA concentration above 150 mg/ml were nor-
malized to 100 mg/ml. Purity of the DNA samples was
assessed with a NanoDrop spectrophotometer (Thermo
Scientific).
Genotyping for the study was performed with the Bead-
Station system with the Human CNV370-Quad BeadChip
(Illumina) for STAAD samples and the Human 660W-
Quad BeadChip (Illumina) for FTAAD samples. Briefly,
genomic DNA was amplified and fragmented prior to
hybridization to the genotyping chip. A single base pair
extension reaction was then performed, followed by stain-
ing with detectable fluorescent dye labels. The resulting
products were imaged with the BeadArray Reader (Illu-
mina). Quality standards for labeling, single base exten-
sion, hybridization, stringency, and nonspecific bind-
ing were verified. Additional quality control thresholds
included standard deviation of normalized intensity values
<0.35, inferred European ancestry by comparison to
HapMap CEU (Utah residents with ancestry from northern
and western Europe) samples (with multidimensional
scaling implemented in PLINK), and >97% call rate of
attempted SNPs. Replicates, unexpected duplicates, or
samples with mismatched gender, excess heterozygosity,
excess homozygosity, or missing genotypes were excluded
from further analysis.
Data Analysis
After allele detection and genotype calling were performed
with Genome Studio software (Illumina), B allele frequen-
cies and logR ratios were exported as text files for PennCNVer 10, 2010
analysis. CNVPartition was run as a plug-in within the
Genome Studio browser with the following settings: confi-
dence threshold 50, minimum number of probes 5.
Sample-level quality control analysis was performed with
PennCNV software. Samples were excluded from further
analysis if any of the following criteria were met: standard
deviation of logR ratios > 0.35, B allele frequency drift >
0.1, waviness factor > 0.05, number of CNVs identified >
2 standard deviations above the mean of each data set.
CNVs in pericentromeric and immunoglobulin regions
were also excluded. Because of technical limitations with
the FTAAD data set, CNV detection was restricted to
311,803 SNPs that are common to the Illumina 370K and
660K platforms, and association tests were limited to
CNVs with a minimum of ten SNPs. Numbers of excluded
genotypes were not significantly different between data
sets.
Base coverage and clustering of CNV intervals was deter-
mined with the Galaxy Web server. Genes that overlap
with TAAD-associated CNVs were identified with the
regional association test function in PLINK.22 CNV regions
called by both PennCNVand CNVPartition were identified
with the overlap function for rare CNVs in PLINK. CNVs
that were present in more than 1% of samples were
defined as copy number polymorphisms and excluded
from comparative analysis. CNVs less than 50 kb in
length were also excluded from case-control association
tests. Expression profiles for CNV genes were determined
with GeneHub-GEPIS.23 For functional analysis, gene
lists were entered into the IPA Web server (Ingenuity
Systems) and the MetaCore Web server (GeneGo, Bioinfor-
matics Software). The significance of associations was
scored with p values derived from two-tailed Fisher’s exact
tests.
Confirmatory Studies
We validated a subset of suspected CNVs via comparative
genomic hybridization (CGH) with custom Agilent oligo-
nucleotide microarrays.18 Array design and hybridizations
were performed according to the manufacturer’s recom-
mended protocols. Briefly, 400 ng of genomic DNA was
digested with restriction enzymes AluI and RsaI and fluo-
rescently labeled with the Agilent DNA Labeling kit.
The test samples were labeled with cyanine 5-dUTP, and
the reference sample was labeled with cyanine 3-dUTP.
Labeled DNA was denatured and preannealed with Cot-
1 DNA and Agilent blocking reagent prior to hybridiza-
tion for 24 hr in a 658C Agilent hybridization oven.
Standard wash procedures were followed. Arrays were
scanned at 5 mm resolution with an Agilent scanner,
and image analysis was performed with default CGH
settings of Feature Extraction software 9.1.1.1 (Agilent
Technologies).
Primers and probes used to detect CNVs with real-time
quantitative PCR were designed with PrimerExpress soft-
ware (Applied Biosystems). Primers were purchased from
Applied Biosystems, Integrated DNA Technologies, andThe AmericanEurofin MWG Operon. Reactions were run on the ABI
7900 real-time PCR system (Applied Biosystems) with the
following cycling parameters: one cycle at 95C for
10 min, followed by 40 cycles at 95C for 15 s and 60C
for 60 s. Each reaction was carried out in a total volume
of 20 ml containing 13 Taqman Universal PCR Master
mix, 900 nM of each primer, 250 nM probe, and 10 ng of
genomic DNA. Copy number was determined by Copy
Caller 1.0 software (Applied Biosystems) with a probe set
within the RnaseP gene as a reference.Gene Ontology and Network Analysis
Functional analysis was performed with the GeneGoMeta-
Core and Ingenuity Pathways Analysis (IPA) databases.
Tables of genes that were found to be enriched within
TAAD-associated CNVs in the BCM, UTHSCH, and FTAAD
cohorts were imported into the MetaCore or IPA Web
servers as individual experiments. All types of copy num-
ber alterations were included together in our analysis.
The significance of biological pathways was estimated
through a variation of Fisher’s exact test, as implemented
inMetaCore and IPA, and was adjusted for multiple testing
via Benjamini-Hochberg analysis, with a false discovery
rate of less than 0.05.Ingenuity Pathways Analysis
Gene networks were algorithmically generated based on
their connectivity to the Ingenuity knowledge base. A
maximum of 35 genes from the input data set was allowed
in each network. Network scores were based on the hyper-
geometric distribution and were calculated via right-tailed
Fisher’s exact test. To present most of the relevant network
data on the same figure, we used the Merge Networks
feature. The resulting figure (Figure 2) is derived from
known interactions between nodes from the top two
networks of each data set.
The significance of associations between genes within
TAAD CNVs and canonical pathways was measured (1) as
a ratio of the number of genes from the data set that
map to the pathway divided by total number of genes
within the canonical pathway and (2) as a p value calcu-
lated via Fischer’s exact test, representing the probability
that the association between the genes and the canonical
pathway is explained by chance alone.MetaCore Analysis
In MetaCore, we performed enrichment analysis of four
independent ontologies: Gene Ontology (GO) biological
processes, canonical pathways, disease categories, and
GeneGo cellular processes, which are based on experimen-
tally validated interactions. Calculation of hypergeometric
p values was similar to IPA. Networks were generated via
Dijkstara’s shortest path algorithm, which connected
nodes from the TAAD experimental data sets by the short-
est directed paths with manually curated interactions from
the MetaCore database.Journal of Human Genetics 87, 743–756, December 10, 2010 745
Figure 1. Flow Diagram of CNV Analysis
The following abbreviations are used: STAAD, sporadic thoracic
aortic aneurysms and dissections; BCM, Baylor College of Medi-
cine; UTHSCH, University of Texas Health Science Center; dbGAP,
Database of Genotypes and Phenotypes. Samples that did not
meet quality thresholds were identified and excluded via func-
tions implemented in the PennCNV package. Rare events larger
than 1 Mb were analyzed separately.
Table 1. Clinical Characteristics of TAAD Study Groups
Sporadic TAAD
p Value
FTAAD
(88)c
BCM
(418)
UTHSCH
(387)
Female 36% 35% NS 26%
Age 63 (12) 63 (12) NS 45 (14)
BMI 27.8 (5.2) 28.0 (6.1) NS 27.5 (5.5)
Smoking 62% 60% NS NA
Hypertension 67% 85% <0.01 NA
Diabetes 5% 7% NS 6%
Maximum aortic
diametera
5.9 (1.2) 5.6 (1.0) NS 5.5 (1.8)
Bicuspid aortic valve 15% 23% <0.01 15%
Dissectionb 47% 49% NS 44%
Stanford type A 33% 26% 0.04 36%
Stanford type B 15% 23% <0.01 8%
Aortic rupture 2% 4% NS 3%
Underwent aortic repair 94% 93% NS 57%
Involvement of
ascending aorta
89% 83% NS 94%
Annuloaortic ectasia
or root replacement
24% 33% NS 34%
The following abbreviations are used: BCM, Baylor College of Medicine cohort;
UTHSCH, University of Texas Health Science Center at Houston cohort; FTAAD,
familial TAAD; p, probability value derived from Fisher’s exact test; BMI, body
mass index (kg/m2); NS, not significant. Categorical variables are shown as
percentages, and continuous variables are shown as mean (standard devia-
tion).
a Aortic diameters were available for 397 BCM patients and 234 UTHSCH
patients.
b Four patients had both Stanford type A and type B dissections.
c With the exception of age, gender, and aortic diagnosis (dissection, Stanford
class, aortic rupture, repair, involvement of ascending aorta), values were
calculated from 68 available records.Results
CNV Discovery in TAAD Cases
The methods used for CNV discovery in cases and controls
with two independent algorithms are outlined in Figure 1.
We also performed CNV analysis of 88 unrelated affected
probands from families with at least two relatives affected
with TAAD (FTAAD cohort). DNA samples from these
individuals were collected and genotyped via identical
methods. The characteristics of the study populations are
shown in Table 1.
In a genome-wide analysis of 392 BCM STAAD patients
(after exclusion of low-quality samples), CNVPartition
detected 1924 CNVs (760 copy gains and 1164 copy los-
ses), with an average of 5 CNVs per individual (0–21) and
a mean length of 294,000 bp (646–18,724,786 bp).
PennCNV detected 8103 CNVs (3346 copy gains and
4757 copy losses), with an average of 20 CNVs per indi-
vidual (1–93) and an average length of 73,000 bp (597–
4145007 bp). A total of 2063 CNVs in 123 separate chro-
mosomal regions containing 380 Mb or 13% of the
genome were detected by both algorithms. The results of
our CNV analysis are summarized in Table 2.
To validate our findings, we amplified nine predicted
rare CNV regions (CNVRs) (involving ABLIM3 [MIM
611305], AKAP13 [MIM 604698], BMPR1B [MIM 603248],
JAG1 [MIM 601920], MYH11, PHLPPL [MIM 611066],
RHOC [MIM 165380], RGNEF [MIM 612790], and SLFN12746 The American Journal of Human Genetics 87, 743–756, Decemb[MIM unassigned]) from genomic DNA via real-time PCR.
Nine genomic DNA samples with eight predicted rare
CNVRs (involving ACTB [MIM 102630], THBS4 [MIM
600715], SPTBN1 [MIM 182790], SPTBN4 [MIM 606214],
SLFN12, MYH11, TGFBR3 [MIM 600742], and DFNB31
[MIM 607084]) were also hybridized to a custom CGH
oligonucleotide array that was designed to interrogate
predicted CNV regions based on our preliminary results.
All of the predicted CNVs were successfully verified. In
pairs of duplicated samples, the rate of concordance for
CNVs determined by the same algorithm was 90%. Inter-
section of CNV calls from two different algorithms enabled
us to derive a high-confidence data set for subsequent
analysis.
To identify risk CNVs for STAAD, we analyzed the
burden of large CNVs in cases and controls. In 392 BCM
patients, we identified 63 copy gains or losses larger than
500 kb (43 duplications, 20 deletions). For comparison,
control genotypes from unaffected adults were selected
from five publicly available cohorts in dbGAP (Table S1).er 10, 2010
Table 2. Summary of CNV Discovery
TAAD
ControlsBCM UT Familial
Number of individuals 392 366 87 4922
Microarray platform 370Q 370Q 660W Multiple
Number of CNVs: PennCNV 8103 8576 664a 146423
Number of CNVs: CNVP 1924 2086 1764 107282
Number of CNVs: Overlap 1025 1038 93 26168
Number of CNVs:
Duplications only
562 493 49 11180
Number of CNVs: >500 kb 193 148 12 2803
Number of CNVs: Rare CNV
regions
47 57 20 ND
Number of CNVs: Percentage
of individuals
11 15 23 ND
Number of genes overlapped
by rare CNVs
186 210 84 ND
Number denotes number of unrelated individuals in each data set with usable
CNV data; PennCNV denotes number of autosomal CNVs detected by
PennCNV algorithm; CNVP denotes number of autosomal CNVs detected by
CNVPartition algorithm; Overlap denotes number of autosomal CNVs detected
by both PennCNV and CNVPartition; ND denotes not determined. Rare CNV
regions are a subset of the overlapping CNVs identified by both algorithms.
a Called with 311,803 SNPs common to 370K and 660K platforms.Multidimensional scaling (as implemented in PLINK)
with HapMap reference populations (CEU, Japanese in
Tokyo, Japan [JPT], and Yoruba in Ibadan, Nigeria [YRI])
was used to select 5088 ethnically matched controls of
European descent from 6809 dbGAP controls. Identical
genotype calling, quality control, and CNV detection
methods were used in STAAD cases and controls. In the
controls, PennCNV and CNVPartition jointly detected
26,168 CNVs in 558 separate chromosomal regions. The
overall prevalence of duplications and deletions, as well
as the percentage of CNVs that are located within gene
boundaries, was significantly increased in STAAD patients
(p < 0.001). Forty-three large CNVs (68%) discovered in
the STAAD cases were also observed in at least one con-
trol individual, whereas 20 large CNVs were unique to
STAAD cases and were not present in controls. These
included a 12 Mb deletion in one individual that over-
laps the critical region defined by linkage analysis for
the FTAAD locus FAA1 in 11q23.3.24 In two other individ-
uals, we identified 800 kb and 1.2 Mb duplications of
16p13.1 involving MYH11, which is also mutated in
FTAAD.10,11 None of the individuals with large CNVs
were found to have associated defects, such as patent duc-
tus arteriosus or bicuspid aortic valves, or other extravas-
cular anomalies.
To discover CNVRs that are enriched in STAAD patients,
we performed association tests with the segmental CNV
data restricted to CNVs less than 1Mb in length via permu-
tation methods implemented in PLINK. We identified 31
CNVRs involving 120 genes that were observed in cases,The Americanbut not in controls, as well as 14 additional CNVRs
involving 66 genes that are more prevalent in cases
compared to controls. The enriched CNVRs are rare (prev-
alence of less than 0.1%) or not present at all in control
individuals. Five of these CNVRs were found in more
than one individual (Table 3). Sixteen of 37 copy gains
are predicted to lead to three intact copies of all affected
genes, with the exception of CNVs that disrupt one allele
of ABRA (MIM 609747), ADAMTS2 (MIM 604539),
BMPR1B (MIM 603248), CALB2 (MIM 114051), CAPZA1
(MIM 601580), CDRT4 (MIM unassigned), COX10 (MIM
602125), CTNNA3 (MIM 607667), DNAJA5 (MIM unas-
signed), DPP10 (MIM 608209), FHOD3 (MIM 609691),
GARS (MIM 600287), LRCH3 (MIM unassigned), MTUS
(MIM 609589), PBLD (MIM 612189), PHLPPL (MIM
611066), RASGRP3 (MIM 609531), RASSF2 (MIM 609492),
RNF24 (MIM 612489), RNF150 (MIM unassigned), RREB1
(MIM 602209), SH3TC1 (MIM unassigned), TAFA2 (MIM
unassigned), TBC1D9 (MIM unassigned), TBC1D14 (MIM
unassigned), and TSSC1 (MIM 608998).Gene Ontology Analysis
To determine whether specific cellular functions are dis-
rupted by STAAD-associated CNVs, we performed gene
ontology and pathway analysis of the 186 genes within
CNVRs that were enriched in BCM STAAD patients
(Table 4). We found that 27 of these genes encode proteins
that are involved in the regulation of the actin-based cyto-
skeleton (GO terms ‘‘Cell Assembly and Organization’’ and
‘‘Cell Morphology,’’ p ¼ 5.2 3 103): ACTR2 (MIM
604221), AFAP1 (MIM 608252), AFAP1L1 (MIM unas-
signed), ABLIM2 (MIM 612544), ABLIM3 (MIM 611305),
HTR4 (MIM 602164), RHOC, CAPZA1, DVL1 (MIM
601365), MYH11, MYPN (MIM 608517), FHOD3, PDLIM5
(MIM 605904), SNAP25 (MIM 600322), NDE1 (MIM
609449), ABCC1 (MIM 158343), SPRY2 (MIM 602466),
POMZP3 (MIM 600587), PAK7 (MIM 608038), JAG1, BLZF1
(MIM 608692), SPTBN4, ABRA, CRHR2 (MIM 602034),
AQP1 (MIM 107776), ADCYAP1R1 (MIM 102981), and
HCN2 (MIM 602780). MetaCore analysis of these genes
also identified pathways that mediate myofibril assembly
(p ¼ 5.9 3 108), elastic fiber assembly (p ¼ 4.9 3 107),
cytoskeleton remodeling (p ¼ 1.7 3 104), and cell adhe-
sion (p ¼ 1.2 3 103) as the most significantly enriched
GO processes. MetaCore and IPA also showed that these
gene products interact together in canonical Rho GTPase
signal transduction pathways (‘‘Actin Cytoskeleton
Signaling,’’ p ¼ 5 3 104, and ‘‘Regulation of Actin-based
Motility by Rho,’’ p ¼ 2.6 3 103). We also analyzed
CNVs that are more prevalent in control individuals com-
pared with TAAD cases, but we did not find signifi-
cant enrichment for cytoskeletal remodeling or other
discrete intracellular processes. The most highly enriched
GO terms for control CNVs were ribosomal RNA (2.9 3
1011), enzyme interaction (1.7 3 108), and cytokine
receptor binding (2.5 3 108).Journal of Human Genetics 87, 743–756, December 10, 2010 747
Table 3. Rare CNV Regions in BCM TAAD Patients
Chr. Band Start Length Gene(s) Copy Cases Controls
1 p36.33 1142494 475171 DVL1, CDC2L2, CDC2L1, MIB2, MMP23B, SSU72, ATAD3A,
ATAD3B, ATAD3C, VWA1, CCNL2, AURKAIP1, MXRA8, SCNN1D,
ACAP3, CPSF3L, PUSL1, UBE2J2, B3GALT6, SDF4, GLTPD1, TAS1R3,
MRPL20
Gainb 2 1
2 q14.1 116135534 531094 DPP10a Gainc 2 0
4 q22.3 95973863 372128 BMPR1Ba Loss/Gainc 2 (U) 0
4 q31.21 141875917 129684 RNF150,a TBC1D9a Loss/Gainc 2 0
16 p13.11 14929488 1509330 MYH11, ABCC6, NOMO2, NDE1, ABCC1, MPV17L, C16ORF45,
C16ORF63, KIAA0430
Gain 2 (U,F) 5
2 p25.3 3342118 419473 ALLC, COLEC11, RPS7, ADI1, RNASEH1, TTC15, TSSC1a Gain 1 0
1 p13.2 111664830 94386 C1ORF88, OVGP1d Loss 1 1
1 p13.2 113015620 449830 RHOC, SLC16A1, CAPZA1,a FAM19A3, PPM1J Gain 1 0
1 q24.2 167524929 225256 BLZF1, C1orf114, SLC19A2, F5 Loss 1 1
2 p22.3 32208994 363359 YIPF4, NLRC4, SPAST,d SLC30A6 Gain 1 0
2 p22.3 33532429 66034 RASGRP3a Gain 1 1
2 p22.1 38371019 376145 HNRPLL, ATL2 Gain 1 0
2 p14 65256382 121219 ACTR2 Gain 1 0
2 p11.2 88684402 246926 SMYD1, FABP1, THNSL2, EIF2AK3, RPIA Loss 1 0
2 q33.3 207353709 198248 CPO, FASTKD2 Loss 1 0
3 q29 199053957 252802 IQCG, LRCH3 Gain 1 1
4 p16.1 6969581 1289129 AFAP1, ABLIM2, SH3TC1,a SORCS2, TBC1D14,a GRPEL1, CCDC96,
TADA2B
Gain 1 0
4 p14 37251646 184002 RELL1, c4orf19 Gain 1 0
5 p15.33 143199 254392 SDHA, CCDC127, PLEKHG4Bd Gain 1 1
5 p13.2 34984289 106107 AGXT2, DNAJA5, PRLR Gain 1 0
5 q33.1 148274871 566620 ABLIM3, AFAP1L1, SH3TC2, HTR4, GRPEL2, PCYOX1L, IL17B Gain 1 (U) 0
5 q33.2 153778073 203294 SAP30L, HAND1 Gain 1 0
5 q35.3 178661437 204439 ADAMTS2a Gain 1 1
6 p24.3 7137785 135061 RREB1,a SSR1, CAGE1a Gain 1 1
7 p22.1 5441935 142828 ACTB, FBXL18 Gain 1 0
7 p15.1 30623992 507188 GHRHR, AQP1, ADCYAP1R1, INMT, FAM188B, CRHR2, GARSa Gain 1 0
8 p22 17741656 153872 PCM1, FGL1, MTUS1d Gain 1 0
8 q23.1 107847500 39522 ABRAa Gain 1 0
10 q21.2 63577609 75066 RTKN2 Loss 1 0
10 q21.3 68672493 1073082 MYPN,d SIRT1, CTNNA3,a HERC4, PBLD,a,d DNAJC12, ATOH7 Gain 1 1
10 q23.31 90129215 158693 C10ORF59 Loss 1 0
12 q14.1 60119327 729214 TAFA2a Gain 1 0
13 q31.1 79702503 154705 SPRY2 Gain 1 0
14 q22.1 51343413 391832 NID2, GNG2,d C14orf166 Gain 1 0
14 q32.33 104688087 65485 JAG2, NUDT14, BRF1 Loss 1 1
16 q22.3 69965031 295906 CALB2,a PHLPPL,a ZNF23, ZNF19, TAT, MARVELD3, CHST4 Gain 1 0
17 p13.1 7162432 58562 NEURL4,a CENTB1, KCTD11,d TMEM95d Gain 1 0
17 p12 14045669 1353365 COX10,a,d CDRT15,d HS3ST3B1,d PMP22, TEKT3, CDRT4a Gain 1 (U) 1
17 q11.2 25958123 504562 CRLF3, ATAD5, ADAP2, RNF135, NF1a Gain 1 0
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Table 3. Continued
Chr. Band Start Length Gene(s) Copy Cases Controls
18 q12.2 32105471 269288 FHOD3a Gain 1 1
18 q23 73094966 704483 GALR1 Gain 1 (F) 1
19 p13.3 532070 94443 EMMPRIN, HCN2, POLRMT, FGF22, RNF126 Loss 1 0
19 q13.2 45748633 171836 SPTBN4, LTBP4, SHKBP1,NUMBL, ITPKC, AKT2,MAP3K10, CNTD2,
TTC9B, C19ORF47, PRX, PLD3, HIPK4, BLVRB, SERTAD1, SERTAD3,
ADCK4
Loss 1 (U) 0
20 p13 3923107 104045 RNF24a Gain 1 0
20 p13 4726754 47646 RASSF2a Gain 1 0
20 p12.2 8044130 5278047 PLCB1, PLCB4, PAK7, SNAP25, MKKS, JAG1, TASP1, BTBD3,
ANKRD5, ISM1, SPTCL3
Loss 1 0
20 q13.11 41356169 184228 SFRS6 Gain 1 0
Chr. denotes chromosome; Start denotes beginning of CNV based on build 36.1 of the reference genome; Length denotes size of CNV in base pairs; Type denotes
duplication (gain) or deletion (loss); Controls denotes prevalence of CNV in control population (4922 individuals). Known aneurysm-associated genes are shown
in bold type; genes that are expressed at above-average levels in SMCs are underlined; presence of CNVRs in UTHSCH (U) or familial (F) groups is indicated by
parentheses.
a Genes that are potentially disrupted by duplications.
b p ¼ 0.02.
c p ¼ 0.006.
d Genes that overlap with 1–2 additional control CNVs.CNV Discovery in Replication Data Set
We then evaluated these findings in an independent
cohort of 387 individuals with STAAD recruited from
UTHSCH. Their demographic characteristics are well
matched with BCM individuals except for a higher inci-
dence of hypertension and more frequent involvement
of the distal aorta (Table 1). CNV detection and analysis
were performed identically for the two data sets. In 366
UTHSCH STAAD patients, CNVPartition and PennCNV
identified 5302 and 8576 copy gain or copy loss events,
respectively. A total of 1038 CNVs were detected by both
algorithms. We identified 56 rare CNVRs (46 gains, 11 los-
ses) that were associated with STAAD in case-control anal-
ysis, including 40 CNVRs involving 161 genes that are
unique to STAAD and not present in controls, as well as
17 additional CNVRs involving 49 genes that are sig-
nificantly more prevalent in cases compared to controls
(Table S2). Nine of the top ten predicted functional cate-
gories for genes within BCM and UTHSCH CNVs were
shared (Table 4). Five CNVRs involving 31 genes (13%) in
4q22.3, 5q33.1, 16p13.1, 17p12, and 19q13.2 were present
in both groups (annotated in Table S2). The CNVR in
16p13.1 involves theMYH11 gene (AAT4). The other recur-
rent CNVRs do not involve loci previously suspected to
play a role in TAAD.
Genes within UTHSCH CNVs are also predicted to
interact within Rho GTPase-mediated actin cytoskeleton-
based pathways. ‘‘Smooth Muscle Contraction’’ (p ¼ 1.0 3
107) and ‘‘Muscle Thick Filament Assembly’’ (p ¼ 6.9 3
107) were the two most highly enriched GO processes.
IPA showed that the 210 genes within UTHSCH CNVs
are enriched for the functional categories ‘‘Cardiovascular
System Development and Function’’ (20 genes, p ¼ 1.8 3
104), ‘‘Molecular Transport’’ (13 genes, p ¼ 5.8 3 105),The Americanand ‘‘Tissue Development’’ (27 genes, p ¼ 3.2 3 104). In
the development category, MetaCore specifically identified
gene networks regulating angiogenesis (p ¼ 2 3 105) or
blood vessel morphogenesis (p ¼ 0.01) among the most
highly enriched functions. These results suggest that dis-
ruption of connective tissue structure or smooth muscle
contractility perturbs vascular integrity and predisposes
to TAAD.
CNV Discovery in Familial TAAD Data Set
We also performed CNV analysis of 88 probands of Euro-
pean ancestry from families with at least two family
members with TAAD but without an identified causative
gene mutation or syndrome (FTAAD cohort) recruited at
UTHSCH. On average, these patients were significantly
younger at diagnosis than STAAD patients (45 years).
However, gender distribution, body mass index, and the
prevalence of aortic dissection were not significantly
different between cohorts. In case-control analysis, we
identified 20 unique or rare CNVRs (15 gains, 5 losses)
involving 84 genes in 87 FTAAD patients (Table S3). In
comparison with STAAD, we found that the overall preva-
lence of rare CNVs in FTAAD patients (23%) was signifi-
cantly increased (Fisher’s exact test, p ¼ 0.03). Fourteen
of the 20 CNVRs were unique to FTAAD. Four of these
regions were also present in individuals with sporadic
disease, including a 3Mb duplication of 16p13.1 involving
MYH11, which is the only event that is present in all three
data sets. None of the genes within the other recurrent
CNVs were previously implicated in vascular disorders.
In one individual, we also identified a 1.4 Mb duplication
of the Williams-Beuren syndrome region in 7q11.23 that
includes the elastin gene (ELN [MIM 130160]). Using
qPCR, we tested relatives of affected probands in threeJournal of Human Genetics 87, 743–756, December 10, 2010 749
Table 4. Gene Functional Categories Enriched in BCM TAAD CNVs
Category UTHSCH FTAAD Genes in CNVs p Value
Cardiovascular disease þ þ CRHR2, SH3TC2, SCNN1D, SNAP25, BMPR1B, ZFPM2, F5, SORCS2,
PLCB1, JAG1, FHOD3, ITPKC, MYH11
0.024
Cardiovascular system
development and function
þ þ CHST4, ZFPM2, ABRA, SMYD1, HCN2, RHOC, DVL1, IL17B, HAND1,
SMYD1
0.023
Cell morphology  þ CRHR2, HTR4, RHOC, DVL1, AQP1, MYH11, ADCYAP1R1, HCN2,
SPRY2, JAG1, BLZF1, ACTB, CAPZA1, AFAP1, AFAP1L1, ABRA, ABLIM2,
ABLIM3, MYPN
0.026
Cell-to-cell signaling and interaction þ þ RHOC, DVL1, BMPR1B, PLCB4, EMMPRIN, SPRY2, TAS1R3, PLCB1,
PAK7, JAG1, ACTN1, CCNL2, SDF4, IL17B, FGF22
0.026
Cellular assembly and organization þ þ ACTR2, HTR4, RHOC, DVL1, MYH11, SNAP25, NDE1, ABCC1, SPRY2,
POMZP3, FABP1, PAK7, JAG1, BLZF1, ACTN1, AFAP1, AFP1L1, ACTB,
CTNNA3, SPTBN4, PDLIM5, FHOD3
0.026
Cellular compromise þ  HTR4, RHOC, ABCC1, DVL1, PLCB1, AQP1, PAK7, PHLPPL 0.027
Cellular development þ þ CCNL2, TNFRSF4, ZFPM2, JAG2, HTR4, SMYD1, SPRY2, FABP1,MYH11,
JAG1
0.024
Cellular growth and proliferation þ þ CCNL2, BMPR1B, TNFRSF4, ADCYAP1R1, RHOC, SPRY2, GHRHR,
FABP1, UGT2B17, MYH11, JAG1, AFAP1, TSSC1, CSNK1A1, JAG2,
MTUS1
0.023
Cellular movement þ þ EMMPRIN, SPRY2, TAS1R3, MYH11, MANEA, ACTB, MYPN, ABRA,
ABLIM2, ABLIM3
0.024
Connective tissue development
and function
þ þ CRHR2, BMPR1B, EMMPRIN, ABCC1, MANEA, NID2, UGDH, MMP23B,
CPO
0.024
Genetic disorder þ þ SDF4, CRHR2, SH3TC2, HTR4, ABCC6, F5, PLCB1, CAPZA1, RHOC,
TBC1D9, ACTB, ALLC, TAT, SNAP25, BMPR1B, PLCB4, ZFPM2,
ADCYAP1R1, EMMPRIN, NDE1, PCM1, ANKRD5, SORCS2, PAK7,
SLC19A2, MOV10, FAM19A2, JAG1, TASP1, FHOD3, DPP10
0.021
Inflammatory response þ þ TNFRSF4, EMMPRIN, ABCC1, FABP1, AQP1, PLCB1, MYH11, IL17B,
ITPKC
0.028
Molecular transport þ þ ABCC6, EMMPRIN, SLC16A1, ABCC1, DVL1, KLB, AQP1, FABP1,
SLC19A2, SNAP25, SLC30A6, SORCS2
0.024
Organ development þ þ BMPR1B, JAG2, ZFPM2, ADCYAP1R1, ABRA, NDE1, SMYD1, SPRY2,
DVL1, GHRHR, FABP1, JAG1, DPP10, MKKS
0.023
Skeletal and muscular system
development and function
þ þ BMPR1B, JAG2, SMYD1, HCN2, MYH11, JAG1, IL17B, HAND1 0.023
Small molecule biochemistry^ þ þ B3GALT6, DVL1, SNAP25, ADI1, THNSL2, ABCC6, UGDH, EMMPRIN,
ABCC1, SLC16A1, KLB, UGT2B17, FABP1, PLCB1, SLC19A2, LIAS
0.024
Category denotes GO molecular processes; þ or  indicate whether or not the same processes are also enriched for genes in UTHSCH or FTAAD CNVs; Genes in
CNVs denotes genes within BCM CNVs that map to GO processes; p value denotes estimated genome-wide significance derived by permutation.families for three different CNVRs and found that they do
not segregate with TAAD (Figure S1). However, one CNVR
(the ELN duplication) appears to be mosaic in the periph-
eral blood of the proband. These findings are consistent
with prior studies showing variable severity and reduced
penetrance of FTAAD.
MetaCore analysis showed that networks regulating
muscle contraction (p ¼ 9.2 3 106), cell adhesion (p ¼
3.1 3 103), and the actin cytoskeleton (p ¼ 5 3 103)
are highly enriched within FTAAD CNVs. The largest IPA
functional categories were derived from actin, myosin,
and Rho GTPase-mediated networks for ‘‘Cellular Move-
ment’’ (10 genes, p ¼ 9.4 3 105) and ‘‘Molecular Trans-
port’’ (10 genes, p ¼ 2.33 104), which were also enriched
in the BCM data set (Table 4). In summary, analysis of GO
annotation enrichment of the CNV genes was consistent750 The American Journal of Human Genetics 87, 743–756, Decembamong these three independent cohorts and strongly
supports our hypothesis that disruption of actin-based
motility is a common and specific element of sporadic
and familial TAAD.
Further analysis with IPA showed that 50 genes within
BCM, UTHSCH, and FTAAD CNVs interact in a common
network that includes components of the extracellular
matrix, intercellular junctions, the actin cytoskeleton,
and nuclear transcription factors (Figure 2). Signal trans-
duction from extracellular matrix receptors to Rho kinase
(ROCK1 [MIM 601702]) and the serum response factor-
myocardin transcriptional complex regulates SMC con-
tractility and the expression of contractile proteins. Sev-
eral genes within this network, including NOTCH1
(MIM 190198), JAG1, MMP9 (MIM 120361), ALOX5
(MIM 152390), JNK1 (MIM 601158), fibulins, and PPIAer 10, 2010
Figure 2. Network of Interacting TAAD CNV Genes
Genes within TAAD-associated CNVs are colored green (FTAAD), orange (BCM), or blue (UTHSCH); lines indicate functional or physical
interactions between gene products; not all genes in the network are shown. All CNVs represented in this network are rare and occur in
one or none of 4922 control individuals. The following abbreviations are used: ABRA, actin-binding Rho-activating protein; ABLIM,
actin-binding LIM protein family; ACAN, aggrecan; ACTR2, actin-related protein 2 homolog; AFAP1, actin filament-associated protein
1; AKAP12, A kinase anchor protein12; ALOX5, 5-lipoxygenase; ARHGAP26, GTPase regulator associated with FAK; ATF2, activating
transcription factor 2; BGN, biglycan; BMP4, bone morphogenetic protein 4; BMPR1B, bone morphogenetic protein receptor 1B;
BMPER, BMP-binding endothelial cell precursor-derived regulator; EPHA5, ephrin type A receptor 5; EMMPRIN, extracellular matrix
metalloproteinase inducer; CAPZA1, capping protein muscle Z-line, alpha 1; CCDC88A, coiled-coil domain containing 88A; CD36,
thrombospondin receptor; CLDN, claudins; COL18A1, collagen type 18, alpha 1 and endostatin; CSRP2, cysteine-rich protein 2;
FAK, focal adhesion kinase; FOG2, friend of GATA2; GDF5, growth differentiation factor 5; HAND1, heart and neural crest derivatives
expressed 1; ID1, inhibitor of DNA binding 1; ILKAP, integrin-linked kinase-associated phosphatase; JAG, jagged homolog; JAM3, junc-
tional adhesion molecule 3; JNK, JUN N-terminal kinase; LIMK1, LIM domain kinase 1; MIB2, mindbomb homolog 2; MMP9, matrix
metalloproteinase 9; MT1-MMP, matrix metalloproteinase 14; MRTFs, myocardin- related transcription factors; MYH11, myosin heavy
chain, smooth muscle isoform; MYL9, myosin regulatory light chain 2, smooth muscle isoform; MYOCD, myocardin; NID2, nidogen 2;
OVOL2, Ovo-like 2; PARD3, partitioning defective 3 homolog; PMP22, peripheral myelin protein 22; POSH, plenty of SH3s; PRKAR2A,
cAMP-dependent protein kinase, regulatory subunit alpha 2; PPIA, cyclophilin A; PRKACA, cAMP-dependent protein kinase catalytic
subunit alpha; PTPRA, protein tyrosine phosphatase, receptor type, alpha polypeptide; RGNEF, Rho guanine nucleotide exchange factor;
RHOC, Ras homolog gene family, member C; ROCK, Rho-associated, coiled-coil domain-containing protein kinase; SMAD, mothers
against decapentaplegic homolog; SMYD1, set andMYND domain-containing 1; SPRY2, sprouty homolog 2; SRF, serum response factor;
TJP1, tight junction protein ZO-1; TNC, tenascin C; VCAN, versican; WASL, Wiskott-Aldrich syndrome gene-like protein; WIPF1, WAS/
WASL-interacting protein family member 1. Figure was derived from IPA analysis (version 8.1) and created with Cytoscape (version
2.6.3).(MIM 123840), have been implicated in the pathogenesis
of aortic aneurysms. The canonical pathway ‘‘Cytoskel-
eton Remodeling: Regulation of Cytoskeleton by Rho
GTPases’’ and themajor functional categories ‘‘Muscle Fila-
ment Assembly,’’ ‘‘Elastic Fiber Assembly,’’ and ‘‘Muscle
Development’’ are shared by the BCM, UTHSCH, and
FTAAD data sets (Figure 3). We also found evidence for
functional interaction between genes in the TAADnetwork
and ACTA2, the smooth muscle a-actin gene that is
mutated in FTAAD. Comparison of vascular SMC gene
expression profiles from explanted murine Acta2-deficientThe Americanand wild-type aortic SMCs showed that highly upregulated
transcripts in ACTA2 null cells were significantly enriched
for genes within TAAD-associated CNVs: MYH11 (8.4-
fold), CDH13 (MIM 601364, 8.1-fold), ELN (8.1-fold),
COL18A1 (MIM 120328, 7.0-fold), INMT (MIM 604854,
6.5-fold), AQP1 (MIM 107776, 6.5-fold), COLEC11 (MIM
612502, 3.9-fold), AKAP12 (2.8-fold), MMP23 (MIM
603320, 2.7-fold), and FOXD1 (MIM 601091, 2.5-fold)
(Fisher’s exact test, p ¼ 0.012). In addition, BMPER (MIM
608699), EFEMP1 (MIM 601548), TNC (MIM 187380),
and FOG2 (MIM 603693) were significantly downregulatedJournal of Human Genetics 87, 743–756, December 10, 2010 751
Figure 3. Gene Ontology Processes in BCM, UTHSC, and FTAAD Cohorts
Negative logarithms of p values are plotted on the x axis. Green: FTAAD; orange: BCM; blue: UTHSCH. Graph was generated withMicro-
soft Excel with data from GeneGo MetaCore pathway analysis software. P values are for enrichment of the specific GO terms. For calcu-
lation of p values, please refer to Subjects and Methods.in Acta2-deficient SMCs (D.M.M., unpublished data).25
These findings implicate a network of genes linking
dynamic changes in the extracellular matrix, cell adhesion,
and vascular smooth muscle contractility to the pathogen-
esis of TAAD.Discussion
TAAD is a multifactorial disease with a significant genetic
component, as illustrated by the fact that patients have
similarly affected family members in 20% of cases, and
the genes identified for familial TAAD demonstrate
reduced penetrance and variable severity.7,8 We found
rare copy number variants in 13% of sporadic TAAD cases
in both the discovery and replication cohorts, as well as
significantly higher numbers of CNVs (23%) in FTAAD
cases. Although the statistical association between any
single rare variant and TAAD does not attain genome-
wide significance, we observed recurrent rare events in
cases that are not present in 5088 controls (Figure S1).
TAAD-associated CNVs were enriched for genes that regu-
late cell adhesion or the actin cytoskeleton through direct
interactions with contractile units containing the smooth
muscle isoforms of actin and myosin. Mutations in genes
encoding these proteins are known to cause FTAAD. Our
findings support a common underlying mechanism for
the pathogenesis of TAAD whereby any one of multiple,
individually rare variants predispose to the disorder by
disruption of SMC function, specifically cell adhesion
and contraction.
The discovery of mutations of SMC-specific actin or
myosin isoforms in FTAAD cases has implicated disruption
of aortic SMC contractile functions in the development of
aneurysms.16 SMC contractile units are distinctly different
from sarcomeres in cardiac or skeletal muscle. Actin and
myosin filaments are anchored to the SMC membrane at752 The American Journal of Human Genetics 87, 743–756, Decembdense plaques found at focal adhesions that contain integ-
rin receptors. These integrin receptors, in turn, bind to
extracellular ligands, including fibrillin in microfibrils
and collagen fibers, which form a supportive lattice around
SMCs in the aortic media. Fibrillin-containing microfibrils
provide the link between SMCs and elastic fibers in elastic
arteries, including the aorta.26 In the cytoplasm, integrins
are linked to the actin cytoskeleton by filamins, dystro-
phins, and other actin-binding proteins. Therefore, inter-
actions between contractile units in SMCs, dense plaques,
microfibrils, and elastic fibers are necessary for SMCs to
generate contractile force and are required to coordinate
contractile and elastic tensions in response to mechanical
stresses imposed on the vessel wall.27 Disruption of any
component is predicted to compromise SMC contractility
and activate stress and stretch pathways in SMCs.16
Our findings indicate that TAAD-associated CNV genes
are enriched in genes involved in an interacting network
that regulates vascular SMC adhesion and contractility.
The network includes the ligands jagged-1 and jagged-2
(JAG1 and JAG2 [MIM 602570]), sprouty-2 (SPRY2), reticu-
lon-4 (RTN4 [MIM 604475]), bonemorphogenetic protein-
binding endothelial precursor-derived regulator (BMPER),
the elastin-associated growth factor endostatin (a proteo-
lytic fragment of the COL18A1 gene product), and VG5Q
(AGGF1 [MIM 608464]), which modify the prolifera-
tion and differentiation of vascular cells during angiogen-
esis or recovery from vascular injury.28–30 The adhesive
glycoproteins tenascin C (TNC), biglycan (BGN [MIM
301870]), nidogen-2 (NID2 [MIM 605399]), fibulin-3
(EFEMP1), elastin microfibril interface-located protein-3
(EMILIN3 [MIM 608929]), and thrombospondins THBS1
(MIM 188060), THBS4, and THSD7A (MIM 612249) facili-
tate interactions between collagen or elastin fibers in the
tunica media and integrin receptors on SMCs.31–34 Their
tissue distributions and functions are similar to fibrillin-1,
and mutations of FBN1 encoding fibrillin-1 cause TAAD iner 10, 2010
patients with Marfan syndrome.35 Elevated expression
of tenascin C is consistently found in ascending aortic
aneurysms.36 We also found rare CNVs that affect the
integrin-associated membrane proteins tetraspanin 1
(TSPAN1 [MIM 613170]), ephrin receptor A5 (EPHA5 [MIM
600004]), extracellular matrix metalloproteinase inducer
(EMMPRIN [MIM 109480]), protein tyrosine phosphatase
A (PTPRA [MIM 176884]), integrin-linked kinase associated
phosphatase (ILKAP [MIM 601646]), junctional adhesion
molecule C (JAM3 [MIM 606871]), and scavenger receptor
type B1 (SCARB1 [601040]). These proteins interact with
integrins and regulate cell migration or adhesion in
response to ligand binding or deformation of the cell
membrane.37–39 Integrins are linked to the actin cytoskel-
eton and SMC contractile units by spectrins, alpha-acti-
nins, and other actin-binding proteins, including myopal-
lidin (MYPN), formins (FHOD3), coactosin-like protein
(COTL1 [MIM 606748]), actin-related proteins (ACTR2),
actin-binding LIM domain proteins (ABLIM2 andABLIM3),
and actin filament-associated proteins (AFAP1 and
AFAP1L1).40,41 These genes are highly expressed in SMCs
and are also disrupted by rare CNVs in TAAD patients.
Based on these results, we conclude that TAAD-associated
CNVs systematically disrupt interactions between vascular
SMCs and the extracellular matrix.
TGF-b ligands and receptors were not enriched in our
data set, although the canonical TGF-b pathway was signif-
icantly overrepresented in STAAD patients. Loss of one
copy of the TGF-b inhibitors LTBP4 (MIM 604710) or
WWP1 (MIM 602307) because of CNVs in three TAAD
patients would be expected to increase TGF-b activity.42,43
Alterations of the TGF-b pathway promote the progression
of aneurysm disease in Marfan syndrome, with implica-
tions for a similar pathogenic role in TAAD.44
Abnormal organization of myofibrils was found in aortic
SMCs from FTAAD patients with ACTA2 mutations.9,10
Depletion of elastin, collagens, fibulins, or fibrillin-1 in
the ECM or uncoupling of SMCs from the ECM cause
similar pathological changes and aortic disease. We
hypothesize that the rare, sporadically occurring CNVs
identified in TAAD patients also compromise SMC contrac-
tility by direct effects on contractile proteins or disruption
of SMC adhesion to the ECM via focal adhesions. Although
these predictions need to be verified with functional
studies in cell and animal models, it is instructive that
CNVs and familial mutations affect a common pathway
that is critical for SMC function.
It is interesting to note that TAAD-associated CNVs
contain several genes known to predispose to arterial aneu-
rysms. The AGGF1 gene encoding the secreted angiogenic
factor VG5Q is mutated in Klippel-Trenaunay-Weber
syndrome (MIM 149000), which is associated with heman-
giomas and large arterial aneurysms. Mutations of JAG1
cause Alagille syndrome (MIM 188450), a developmental
disorder with arterial aneurysms in 10% of cases, as well
as multiple extravascular manifestations. A large deletion
involving JAG1 was also reported in a single individualThe Americanwith isolated sporadic tetralogy of Fallot, which is associ-
ated with the late development of aortic root dilation
and ascending aneurysms in 12%–20% of patients after
surgical repair.20,45 Mutations in the transcription factor
FOG2 (also known as ZFPM2) have also been described in
tetralogy of Fallot and are associated with cardiovascular
developmental defects in mice.46,47 ELN mutations cause
thoracic aortic aneurysms in association with autosomal-
dominant cutis laxa (MIM 123700), and larger deletions
that include ELN contribute to aortic and pulmonary
artery defects in individuals with Williams-Beuren syn-
drome (MIM 194050). However, the association between
microduplications of this region and TAAD is currently
unknown.48 MYH11 is mutated in 1%–2% of FTAAD cases
with a distinctive phenotype of TAAD associated with
a patent ductus arteriosus (AAT4 [MIM 132900]), but simi-
larly the association of duplications of this region and
TAAD has not been identified.10,49 In addition, ACTB,
SLC2A11 (MIM 610367), and EFEMP1 interact with or are
paralogs of genes that are implicated in other aneurysm
disorders. TAAD patients with these and other rare variants
do not possess distinguishing clinical features or extravas-
cular abnormalities.
In addition to the 16p13.1 duplications involving
MYH11, unique CNVs in TAAD patients contain genes
with known vascular functions. Duplications of galanin
receptor 1 (GALR1 [MIM 600377]) are present in BCM
and FTAAD patients. Galanin is a peptide hormone with
potent vasodilatory effects that modulates smooth muscle
contractility.50 EMILIN-3 is a secreted glycoprotein that
interacts with elastin in the arterial wall.32 Mutation of
a closely related paralog (EMILIN1 [MIM 130660]) causes
aortic defects with connective tissue abnormalities in
mice.51 We identified recurrent disrupting duplications of
EMILIN3 in UTHSCH and FTAAD patients. Inhibition of
bone morphogenetic protein and Notch signal transduc-
tion by BMPER and OVOL2 (MIM unassigned), respec-
tively, is required for normal vascular development in
mice and zebrafish,29,52 and deficiency of biglycan (BGN)
causes spontaneous thoracic aortic dissections in mice.53
Alterations in the expression of these genes may increase
the vulnerability of the aorta to mechanical or oxidative
stress and predispose to aneurysm formation.
TAAD patients harbor a remarkable number of rare CNVs
that are enriched for genes known to be involved in TAAD
or other vascular disorders. We identified a total of 84
CNVRs, as well as larger chromosomal aberrations that
are unique to TAAD patients and not present in 5088
controls. The CNV-associated gene set identified in indi-
viduals with TAAD contains excess duplications and dele-
tions of protein-encoding genes compared with controls.
Because 13% of STAAD patients harbor these rare variants,
CNVs may contribute to a greater proportion of TAAD
cases than single gene mutations. Limitations of our study
include the confounding and unpredictable influence
of multiple Illumina platforms on CNV discovery and
the absence of familial samples that might be used toJournal of Human Genetics 87, 743–756, December 10, 2010 753
adjudicate the CNV findings. The pathway analysis is
based on curated knowledgebases that may not include
biologically relevant interactions, and this may lead to
bias toward detecting well-defined pathways. Our results
also do not include CNVs that were detected by a single
algorithm or genes that are adjacent to CNV boundaries
and are, therefore, likely to underestimate the overall
impact of CNVs in TAAD. The burden of rare CNVs that
we discovered in TAAD is consistent with what has been
described in autism and in tetralogy of Fallot, a comparable
cardiovascular developmental disorder that predisposes
to aneurysm formation.20 Our findings provide strong
support for the involvement of multiple rare genic CNVs,
both genome-wide and at specific loci in TAAD, and have
implications for other adult-onset cardiovascular disorders.Supplemental Data
Supplemental Data include four tables and one figure and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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